Person who experienced the adverse event (patient)
| Event ID | CASE | I F COD | FOLL SEQ | IMAGE | EVENT DT | MFR DT | FDA DT | REPT COD | MFR NUM | MFR SNDR | AGE | AGE COD | GNDR COD | E SUB | WT | WT COD | REPT DT | OCCP COD | DEATH DT | TO MFR | CONFID | REPORTER COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4524964 | 5695245 | I | 4524964-0 | 20030501 | 20030610 | 20041117 | PER | C2003-1434.01 | MYLAN PHARMACEUTICALS INC. | 47 | YR | F | N | 20030926 | PH |
Drug(s) used by person
| Event ID | DRUG SEQ | ROLE COD | DRUGNAME | VAL VBM | ROUTE | DOSE VBM | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4524964 | 1005483622 | PS | CLOZAPINE | 1 | ORAL | 100MG QAM, 200MG AT 2PM, 300MG QHS, ORAL | D | D | 75417 |
Indications of drugs used
| Event ID | DRUG SEQ | INDI PT |
|---|---|---|
| 4524964 | 1005483622 | SCHIZOAFFECTIVE DISORDER |
Outcome of event
| Event ID | OUTC COD |
|---|---|
| 4524964 | OT |
Reactions reported
| Event ID | PT |
|---|---|
| 4524964 | WHITE BLOOD CELL COUNT INCREASED |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | RPSR COD |
|---|---|
| 4524964 | HP |
Therapies reported
| Event ID | DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|
| 4524964 | 1005483622 | 20030513 |